Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Takashi Sugisawa"'
Autor:
Sohei Tsukita, Tetsuya Yamada, Kei Takahashi, Yuichiro Munakata, Shinichiro Hosaka, Hironobu Takahashi, Junhong Gao, Yuta Shirai, Shinjiro Kodama, Yoichiro Asai, Takashi Sugisawa, Yumiko Chiba, Keizo Kaneko, Kenji Uno, Shojiro Sawada, Junta Imai, Hideki Katagiri
Publikováno v:
EBioMedicine, Vol 15, Iss C, Pp 163-172 (2017)
Major symptoms of diabetes mellitus manifest, once pancreatic β-cell numbers have become inadequate. Although natural regeneration of β-cells after injury is very limited, bone marrow (BM) transplantation (BMT) promotes their regeneration through u
Externí odkaz:
https://doaj.org/article/b378414ea3c8407c863d829ecbcd8641
Autor:
Yumiko Chiba, Tetsuya Yamada, Sohei Tsukita, Kei Takahashi, Yuichiro Munakata, Yuta Shirai, Shinjiro Kodama, Yoichiro Asai, Takashi Sugisawa, Kenji Uno, Shojiro Sawada, Junta Imai, Kazuhiro Nakamura, Hideki Katagiri
Publikováno v:
PLoS ONE, Vol 11, Iss 3, p e0150756 (2016)
Selective sodium glucose cotransporter-2 inhibitor (SGLT2i) treatment promotes urinary glucose excretion, thereby reducing blood glucose as well as body weight. However, only limited body weight reductions are achieved with SGLT2i treatment. Hyperpha
Externí odkaz:
https://doaj.org/article/757ebc58e8014a75a2c8d226d47bad33
Autor:
Kei Takahashi, Yumiko Chiba, Shinjiro Kodama, Shojiro Sawada, Sohei Tsukita, Yoichiro Asai, Keizo Kaneko, Junta Imai, Hironobu Takahashi, Shinichiro Hosaka, Takashi Sugisawa, Yuta Shirai, Junhong Gao, Tetsuya Yamada, Kenji Uno, Hideki Katagiri, Yuichiro Munakata
Publikováno v:
EBioMedicine
EBioMedicine, Vol 15, Iss C, Pp 163-172 (2017)
EBioMedicine, Vol 15, Iss C, Pp 163-172 (2017)
Major symptoms of diabetes mellitus manifest, once pancreatic β-cell numbers have become inadequate. Although natural regeneration of β-cells after injury is very limited, bone marrow (BM) transplantation (BMT) promotes their regeneration through u
Autor:
Takashi Sugisawa, Toru Suzuki, Yasushi Ishigaki, Shojiro Sawada, Takeyoshi Murano, Tetsuya Yamada, Sohei Tsukita, Takashi Yamaguchi, Shinjiro Kodama, Hideki Katagiri, Junta Imai
Publikováno v:
Internal Medicine. 55:1131-1136
Lipoprotein lipase (LPL) deficiency is a rare monogenic disorder that manifests as severe hypertriglyceridemia. Whether or not LPL deficiency accelerates the development of atherosclerosis remains controversial. We herein report a 66-year-old woman w
Autor:
Jun-ichi Miyazaki, Yumiko Chiba, Kenji Uno, Hideki Katagiri, Junta Imai, Shinjiro Kodama, Keizo Kaneko, Shojiro Sawada, Makoto Kanzaki, Yoichiro Asai, Tetsuya Yamada, Takashi Sugisawa, Yuichiro Munakata, Yuta Shirai, Hiroyasu Hatakeyama, Kei Takahashi, Sohei Tsukita, Yoshitomo Oka
Publikováno v:
Scientific Reports, Vol 8, Iss 1, Pp 1-11 (2018)
Scientific Reports
Scientific Reports
Olfactory receptors (ORs) mediate olfactory chemo-sensation in OR neurons. Herein, we have demonstrated that the OR chemo-sensing machinery functions in pancreatic β-cells and modulates insulin secretion. First, we found several OR isoforms, includi
Autor:
Yasuhiro Nakamura, Yuta Shirai, Kenji Uno, Hideki Katagiri, Yoshiyuki Ueno, Midori Honma, Nariyasu Mano, Sohei Tsukita, Yumiko Chiba, Masanori Ikeda, Shinjiro Kodama, Keizo Kaneko, Tooru Shimosegawa, Hiroaki Yamaguchi, Kozo Tanaka, Kei Takahashi, Yasuteru Kondo, Takashi Sugisawa, Yuichiro Munakata, Shojiro Sawada, Yoichiro Asai, Masamitsu Maekawa, Tetsuya Yamada, Hironobu Sasano, Keigo Murakami, Junta Imai
Publikováno v:
Gastroenterology.
Background & Aims Hypoxia-inducible factor 1α subunit (HIF1A) is a transcription factor that controls the cellular response to hypoxia and is activated in hepatocytes of patients with nonalcoholic fatty liver disease (NAFLD). NAFLD increases the ris
Autor:
Kei Takahashi, Yumiko Chiba, Shinjiro Kodama, Kazuhiro Nakamura, Yuta Shirai, Tetsuya Yamada, Kenji Uno, Shojiro Sawada, Hideki Katagiri, Yoichiro Asai, Yuichiro Munakata, Junta Imai, Takashi Sugisawa, Sohei Tsukita
Publikováno v:
PLoS ONE
PLoS ONE, Vol 11, Iss 3, p e0150756 (2016)
PLoS ONE, Vol 11, Iss 3, p e0150756 (2016)
Selective sodium glucose cotransporter-2 inhibitor (SGLT2i) treatment promotes urinary glucose excretion, thereby reducing blood glucose as well as body weight. However, only limited body weight reductions are achieved with SGLT2i treatment. Hyperpha